Estrogen Receptor Positive Tumor Completed Phase 2 Trials for Eribulin (DB08871)

IndicationStatusPhase
DBCOND0050145 (Estrogen Receptor Positive Tumor)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01439282Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast CancerTreatment